TP53 and cancer: Studies reported that LIF can activate several oncogenic signaling pathways (e.g., AKT, mTOR, and STAT3 pathways), as well as inhibit tumor suppressive function of p53 in cancer cells, which in turn contribute to the oncogenic activity of LIF in cancers [5, 8–11, 13, 14].